The invention provides a novel quantitative method for differentiating and identification of changes in tissue by enhancing differences in blood flow prior to administering a radiopharmaceutical, which differentially accumulates in tissue based upon differences in blood flow and metabolic activity. In one embodiment the enhancing agent is 0.852 mg per kilogram body weight dipyridamole and the radiopharmaceutical is Technetium-99m hexakis 2-methoxyisobutylisonitrile (sestamibi) and the tissue differentiation is calcification, normal, inflammatory, precancerous and cancerous breast tissue. The present invention allows differentiation between regions of calcification, nonliving or metabolically inactive tissue, normal tissue, pre-cancerous and cancerous tissue. The present invention allows for quantification of changes in tissue to determine the effect of treatment upon tissue.
